Related Experiment Videos
Evaluation of decision rules for frequency-doubling technology screening tests.
Stuart K Gardiner1, Douglas R Anderson, Murray Fingeret
1Discoveries in Sight Research Labs, Devers Eye Institute, Legacy Clinical Research and Technology Center, Portland, Oregon 97208-3950, USA. sgardiner@deverseye.org
Summary
Confirming abnormal results with frequency-doubling technology (FDT) perimetry improves specificity for glaucoma screening, despite a slight decrease in sensitivity. This aids in selecting optimal decision rules.
Area of Science:
- Ophthalmology
- Medical Imaging
- Diagnostic Technology
Background:
- Glaucoma is a leading cause of irreversible blindness worldwide.
- Early detection of glaucoma is crucial for timely intervention and vision preservation.
- Frequency-doubling technology (FDT) perimetry is a potential screening tool for glaucoma.
Purpose of the Study:
- To investigate and compare the effectiveness of various decision rules for frequency-doubling technology (FDT) perimetry screening.
- To evaluate the sensitivity and specificity of different FDT screening criteria in distinguishing between normal and glaucoma subjects.
Main Methods:
- A total of 218 subjects (78 with glaucoma, 140 normal) were recruited across three centers.
- Each subject underwent two FDT perimetry screening tests.
- Fifteen distinct decision rules were applied to the collected FDT data for analysis.
Main Results:
- Estimated specificities for the decision rules varied from 78% to 99%.
- Estimated sensitivities ranged from 40% to 72%.
- Optimal criteria suggested include a cluster of two or more adjacent abnormal locations (p < 2%) with confirmation, or a single highly abnormal location (p < 1%) with confirmation.
Conclusions:
- Confirming abnormal FDT screening results by repeating the test significantly enhances specificity.
- The minor reduction in sensitivity due to confirmation is outweighed by the gain in specificity.
- These findings offer valuable guidance for selecting appropriate decision rules for FDT glaucoma screening.